Sanofi Dupixent Sales Soar 33% to $4.9B, Dividend Rises 19%
Sanofi's Dupixent global net sales jumped 33% to $4.9B in Q1, driving its collaboration revenue to $1.6B as the immunology blockbuster outpaced expectations. The company boosted its quarterly depository receipt dividend by 19% to $2.42, marking the third straight year of double-digit shareholder returns.
1. Dupixent Sales Surge
Sanofi recorded $4.9B in global net sales for Dupixent during Q1 2026, a 33% increase from the prior-year period driven by expanded immunology indications and market share gains.
2. Collaboration Revenue Growth
Revenue shared with Regeneron under the Dupixent collaboration climbed 36% year-over-year to $1.6B, reflecting strong royalty and profit-split contributions from increased product volume.
3. Dividend Increase
The company approved a 19% increase to its quarterly depository receipt dividend, raising it to $2.42 per ADR as part of an ongoing capital return strategy.